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NOD1 and 2 are intracellular sentinels critical to innate immunity. In this issue of Immunity, Bertrand et al.
(2009) fill in a gap in the NOD signaling cascade by demonstrating that cIAP1 and 2 function as E3 ubiquitin
ligases for the RIP2 signaling molecule.Detection of pathogens through con-
served pathogen-associated molecular
patterns is one of the first lines of defense
in inducing and shaping the immune re-
sponse. Recognition of these conserved
features occurs in the host through a
diverse range of receptors including the
RIG-1-like receptors (RLR), Toll-like re-
ceptors (TLR), and the nucleotide-binding
domain-leucine-rich repeat-containing
molecules (NLR). With respect to the
NLR family, the two best-characterized
receptors are NOD1 and NOD2. Both of
these proteins function as intracellular
sensors to detect two structurally distinct
forms of bacterial peptidoglycan pro-
duced by either Gram-negative or Gram-
positive bacteria.WhereasNOD1 is selec-
tive for meso-diaminopimelic acid (DAP)
found in Gram-negative bacteria, themur-
amyl dipeptide MurNac-L-Ala-D-isoGln
(MDP) produced by Gram-positive ba-
cteria is recognized by NOD2 (Kanneganti
et al., 2007).
Ligation of either receptor with the
appropriate ligand activates several sig-
naling cascades, including MAP kinases
and signaling pathways upstream of the
transcription factor NF-kB. Initiation and
propagation of signal transduction re-
quires several phosphorylation, cleavage,
or ubiquitination events, or combinations
of these. Indeed, activation of NF-kB
signaling requires phosphorylation of the
inhibitory IkBa protein followed by conju-
gation of K48-linked polyubiquitin chains
andsubsequent proteosomal degradation.
Ubiquitination, however, does not always
result in degradation; conjugation of K63-
linked ubiquitin to proteins can act as
a scaffold that allow for recruitment of
signaling components in close approxima-
tion to one another. With respect to NOD1
and 2 signaling, binding of agonists in-duces ubiquitination of receptor-interact-
ing protein 2 (RIP2), allowing recruitment
of TGF-b-activated kinase 1 (TAK1) and
subsequent activation of MAPK and
NF-kB pathways (Hasegawa et al., 2008).
Although the conjugation of ubiquitin to
RIP2 has previously been shown to require
an E1 ubiquitin-activating enzyme and the
E2 ubiquitin-conjugating enzyme ubc13-
uev1a complex, the identity of theE3 ligase
was not clear.
Recently, the inhibitor of apoptosis
proteins cIAP1 and cIAP2 were shown to
possess C-terminal RING-finger domains
with E3 ligase activity, and both were
previously demonstrated to ubiquitinate
RIP1 after TNF-a stimulation (Bertrand
et al., 2008). Noting that RIP1 has a high
degree of structural homology to RIP2,
in this paper Bertrand et al. (2009) exam-
ined whether cIAP1 and cIAP2 also func-
tion as E3 ligases of RIP2 after stimulation
of NOD1 or NOD2.
If either protein functioned as an E3
ubiquitin ligase for RIP2, the absence of
these proteins would prevent NOD
ligand-induced signaling. In validation of
this, siRNA targeting of cIAP1 or cIAP2
in a human colonic epithelial cell line
(HT-29) prevented DAP-induced (NOD1-
dependent) production of TNF-a and
monocyte chemotactic protein-1 (MCP-1)
to a similar extent as knockdown of RIP2.
Interestingly, whereas siRNA targeting
of cIAP1 prevented DAP-induced in-
creases in TNF-a and MCP-1, IL-8 pro-
duction was not reduced. This appears
tobedue todifferential effectsonsignaling
induced by DAP. Whereas gene targeting
of either cIAP1 or cIAP2 prevented IkBa
degradation and JNK phosphorylation,
activation of the p38 MAPK kinase
pathway occurred in the absence of cIAP1
but not cIAP2. Bertrand et al. (2008) inves-Immunittigated the response of bone marrow-
derived macrophages (BMDM) from
cIAP1-deficient (Birc2/), cIAP2-defi-
cient (Birc3/), and WT mice to MDP
(NOD2-dependant ligand) to highlight
that these effects are not restricted to
a single cell line or to epithelial cells. Defi-
ciency in either cIAP1 or cIAP2 was asso-
ciated with reduced production of IL-1b,
IL-6, IL-10, and TNF-a upon stimulation.
Together, these findings suggest that the
role for cIAP1 and cIAP2 in NOD-induced
signaling is a conserved mechanism as
opposed to a cell lineage-specific effect.
If cIAP1 and cIAP2 are RIP2 E3 ligases,
then an obvious prerequisite would be the
physical interaction of these proteins. In
agreement with earlier findings, Bertrand
et al. (2009) confirm the physical inter-
action between cIAP2 and RIP2 and
further demonstrate cIAP1-RIP2 bind-
ing. All of these proteins contain CARD
domains that enable binding via CARD-
CARD interactions, so the requirement
of these domains was investigated. Muta-
tion of CARD domains in RIP2 and cIAP1
and cIAP2 did not reduce binding be-
tween these proteins, demonstrating that
these interactions occur independently
of CARD-CARD interactions. Perhaps
more importantly in establishing whether
cIAP1 and 2 are RIP2 E3 ligases, expres-
sion of wild-type but not E3 inactive
mutants of cIAP1 or cIAP2 induced polyu-
biquitination of RIP2. Subsequent experi-
ments with wild-type or mutant forms of
ubiquitin that could only be K48 or K63
linked, demonstrating that cIAP1 and 2
both conjugate both types of ubiquitin to
RIP2. Curiously, TRAF6, which was used
as a positive control in these experiments,
failed to cause the polyubiquitination
of RIP2. Although these data conflict
with previous observations (Yang et al.,y 30, June 19, 2009 ª2009 Elsevier Inc. 755
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Previews2007), the suggestion by Bertrand et al.
(2009) that TRAF6 serves not as an E3
ligase but as an adaptor protein required
for NOD agonist-induced NF-kB activa-
tion is plausible. Suggestive of this, it
was previously noted that ubiquitination
of TRAF6 is greatly diminished in the
absence of RIP2 (Abbott et al., 2007).
This remains an area of contention and
will require further studies to clearly eluci-
date the role of TRAF6 in RIP2 polyubiqui-
tination.
To clarify the importance of cIAP1 and 2
in modulating immunity in vivo, Bertrand
et al. (2009) characterized the response
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Figure 1. cIAPs Orchestrate NOD-Induced
Signaling
Detection of bacterially derived DAP by NOD1 and
MDP by NOD2 result in cIAP1 and 2 binding to
RIP2. Both cIAP1 and cIAP2 function as E3 ligases
of RIP2, resulting in the conjugation of K63 poly-
ubiquitin chains to RIP2. These events precede
binding and activation of TAK1, which is required
to initiate NF-kB and MAPK signaling.756 Immunity 30, June 19, 2009 ª2009 Elsevto NOD1 or NOD2 agonists in cIAP1-
or cIAP2-deficient mice. As anticipated,
Birc2/ and Birc3/ mice exhibited a
substantial reduction in serum cytokines
and chemokines after i.p. injection of
DAP or MDP. As a consequence of this
reduced chemokine production, substan-
tially reduced infiltration of neutrophils
occurred in Birc2/ and Birc3/ com-
pared to WT mice. These data indicate
that the initiation of NOD1- and 2-elicited
immune responses require cIAP1 or cIAP2
in vivo. Although these experiments high-
light the need for cIAP1 and 2 to induce
protective immunity, what about scenarios
where NOD signaling is protective through
downregulation of immune responses?
To answer this question, Bertrand et al.
(2009) have made use of the previous
observation that administration of MDP
prevents chemically induced colitis (Wa-
tanabe, 2008). The procolitic agent de-
xtran sodium sulfate (DSS) is a sulfated
polymer that is toxic to epithelial cells,
damaging the mucosal barrier, and allow-
ing the commensal flora access to the
lamina propria. The resulting mucosal
inflammation is largely B and T cell inde-
pendent, with proinflammatory cytokines
produced bymacrophages. DSS-induced
colitis results in mucosal ulceration, co-
lonic shortening, weight loss, increased
ion secretion, and diarrhea. As previously
reported, treatment of WT mice with
MDP reduced the severity of colitis, as in-
dicated by decreasedweight loss, colonic
inflammation, and serum concentration of
the acute phase protein SAA. This protec-
tive effect of MDP was completely lost
in either RIP2-deficient (Ripk2/) or
Birc3/ mice, demonstrating that the
IAPs are critical in mediating NOD-
induced signaling to limit inflammation.
Although it is tempting to speculate that
failure of protection could be due to
reduced IL-10 production after MDP stim-
ulation, as was observed in cIAP1- and
cIAP2-deficient BMDM in vitro, this is not
probable. Protection afforded by MDP is
independent of IL-10 immunosuppres-
sion, with reduced cytokine production
and blunted responses to TLR agonists
because of increased expression of theier Inc.transcription factor IRF4 (Watanabe,
2008). Although the identification of
cIAP1 and 2 as E3 ligases of RIP2 is
exciting, perhaps caution is warranted in
expecting the translation of knowledge to
the clinic. Highlighting the need for addi-
tional study in NOD signaling in humans,
a recent paper demonstrates divergent
effects of polymorphisms in human and
mouse NOD2 proteins (Noguchi et al.,
2009).
The data presented by Bertrand et al.
(2009) fill in a key gap in the signaling
model (Figure 1), with detection of NOD
agonists leading to the recruitment and
polyubiquitination of RIP2 by cIAP1 or
cIAP2. This modification of RIP2 permits
TAK1 binding and subsequent MKK and
IKK activation, resulting in MAPK- and
NF-kB-dependent gene transcription. As
such, cIAP1 and 2 are keystones in NOD
signaling to induce protective immunity,
or fine-tune the innate immune response
by blunting TLR signaling. Further study
is required to ensure that the current
signaling paradigm is as conserved
between mice and humans as it appears
today.
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